Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Jenkins (Nottingham , United Kingdom), T. Maher (London, United Kingdom), V. Cottin (Lyon , France), Y. Nishioka (Tokushima, Japan), I. Noth (Charlottesville, Virginia, United States of America), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), M. Selman (Mexico City , Mexico). Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial. 2254

Member's Comments

No comment yet.

Related content which might interest you: Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Assessment of blood biomarkers in patients with IPF under antifibrotic therapy Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Effect of nintedanib on multidimensional evaluation in patients with IPF Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD) Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009